An interventional study of Cold-dry air provocation and Warm-moist air provocation in Vasomotor Rhinitis, sponsored by Associated Scientists to Help Minimize Allergies. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Associated Scientists to Help Minimize Allergies · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Rhinitis with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Rhinitis · United States.
Among the 63 studies in Rhinitis with a site in United States, this one is the 40th largest by enrollment of the 53 interventional ones that give a count, is one of 9 that started in 2006, is one of 25 with no phase, and was the 12th registered.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
Browse Rhinitis studies →3 of the 63 studies in Rhinitis with a site in United States are open now. Recruiting first, the newest first:
Aventix Medical Inc. · Sites in United States
Ages 18–85
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
Endeavor Health · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 9 · Phase 4 9
First in 2000; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 187 interventional studies indexed under Rhinitis.
Median enrollment 64 across the 53 interventional studies, 67 across the 10 observational. Of the 53 that completed or were terminated, 29 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 63 have an industry lead sponsor. The 10 most frequent:
Associated Scientists to Help Minimize Allergies is the lead sponsor of 3 studies on the registry; none are open to participants now.
Associated Scientists to Help Minimize Allergies has 1 study filed under Rhinitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Rhinitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT05937308Neurent MedicalNEUROMARK Registry Study | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 63 studies in Rhinitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to compare patients with vasomotor rhinitis ("perennial nonallergic rhinitis," "idiopathic rhinitis") with normal controls with respect to their nasal physiologic reactivity to cold air challenge. Ten vasomotor rhinitis (VMR) patients with nasal symptoms triggered predominantly by cold air, four VMR patients with symptoms triggered predominantly by chemicals, and ten nonallergic, non-rhinitic control subjects will be studied.
After initial screening and verification that subjects can cooperate with active posterior rhinomanometry, subjects will be scheduled for two 15-minute exposure sessions with either: cold-dry air, or warm-moist air. Subjects will rate symptoms (and have their nasal airway resistance measured in triplicate) prior to exposure and at 15-min. intervals post-exposure until an hour has passed.
Inclusion Criteria:
(cases; n = 14 total; 10 with predominantly "physical" and 4 with predominantly "irritant"triggers):
A significant history of chronic and/or recurrent nasal symptoms (rhinorrhea, blockage,sneezing or pruritus) in response to:
Exclusion Criteria:
(controls; n = 10):
Exclusion criteria:
(all subjects; n = 24):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
Other: Cold-dry air provocation · Other: Warm-moist air provocation
Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
Other: Cold-dry air provocation · Other: Warm-moist air provocation
15 minute exposure to cold-dry air by nasal mask
15 minute exposure to warm-moist air by nasal mask
Net Proportional Change in Nasal Airway Resistance
Net proportional change in nasal airway resistance, pre- to post-exposure, cold air minus warm air day, calculated as a time-weighted average over the 1.0 h post-exposure. At each time point (pre-exposure, immediately post-exposure, and at 15-, 30-, 45- and 60 minutes post-exposure), nasal airway resistance (in Pa/L/sec) was measured in triplicate. The average of each of these measures was taken for each time point. The time-weighted average of these averages was then calculated for the post-exposure time points and compared with the baseline average for that individual on that testing day. The proportional change from baseline on that day was then calculated (unit-less measure). The difference between the pre-to-post change on the cold air day minus the pre-to-post change on the warm air day was then calculated (unit-less measure). The net proportional change corrects for both inter- and intra-individual variability, which in the case of nasal airway resistance is considerable.
Time frame: One hour
| Milestone | Cold-dry Air Followed by Warm-moist Air | Warm-moist Air Followed by Cold-dry Air |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Net proportional change in nasal airway resistance, pre- to post-exposure, cold air minus warm air day, calculated as a time-weighted average over the 1.0 h post-exposure. At each time point (pre-exposure, immediately post-exposure, and at 15-, 30-, 45- and 60 minutes post-exposure), nasal airway resistance (in Pa/L/sec) was measured in triplicate. The average of each of these measures was taken for each time point. The time-weighted average of these averages was then calculated for the post-exposure time points and compared with the baseline average for that individual on that testing day. The proportional change from baseline on that day was then calculated (unit-less measure). The difference between the pre-to-post change on the cold air day minus the pre-to-post change on the warm air day was then calculated (unit-less measure). The net proportional change corrects for both inter- and intra-individual variability, which in the case of nasal airway resistance is considerable.
| proportional change (unit-less) | Cases | Controls |
|---|---|---|
| Net Proportional Change in Nasal Airway Resistance | 0.11 ± 0.27 | 0.04 ± 0.16 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cases | — | 0/14 (0%) | 0/14 (0%) |
| Controls | — | 0/10 (0%) | 0/10 (0%) |
| Age, Categorical(Participants) | Cases | Controls | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 10 | 24 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Cases | Controls | Total |
|---|---|---|---|
| Mean | 36.9 ± 10.5 | 32.7 ± 14.6 | 35.1 ± 12.2 |
| Sex: Female, Male(Participants) | Cases | Controls | Total |
|---|---|---|---|
| Female | 10 | 7 | 17 |
| Male | 4 | 3 | 7 |
| Region of Enrollment(participants) | Cases | Controls | Total |
|---|---|---|---|
| United States | 14 | 10 | 24 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2006, a primary completion of Oct 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Associated Scientists to Help Minimize Allergies